Details

Last Funding Type

Series B

Last Funding Money Raised

$10M

Industries

Biotechnology,Pharmaceutical

Founded date

Jan 1, 2011

Number Of Employee

11 - 50

Operating Status

Active

Legal Name

Allegro Ophthalmics, LLC

Allegro Ophthalmics is a late-stage ophthalmic biopharmaceutical company focused on redefining the retina space with integrin inhibition therapy, a potential market-disrupting class of drugs for the treatment of retinal diseases. Allegro’s lead investigational drug, risuteganib (Luminate), a broad-spectrum integrin inhibitor, downregulates oxidative stress upstream, at its source, simultaneously affecting all four pathways of oxidative stress that contribute to retinal diseases such as diabetic macular edema (DME) and nonexudative age-related macular degeneration (dry AMD).

Risuteganib has successfully met the endpoints for three Phase 2 studies and is preparing to enter Phase 3 studies in DME during the first half of 2019. In addition, risuteganib is being studied in a Phase 2 trial for the treatment of dry AMD with topline results anticipated in Q3 2019.

Allegro is working closely with the global retina community to bring to market new treatment options for leading causes of blindness and is committed to offering patients an improved quality of life sustained by self-sufficient, functional vision.